Parkinsons Disease Treatment Pipeline Targeting Functional Processes Over Genes
The Parkinson’s Disease (PD) treatment pipeline is characterized by a high degree of innovation and diverse molecular targets, with 37% of 302 products holding first-in-class status, says business intelligence provider GBI Research.
The company’s latest report* states that 90 first-in-class programmes, acting on 39 first-in-class targets, have been identified in early development. Of these products, the majority are involved in functional processes related to PD, giving them the neuroprotective potential to delay or even halt disease progression.
Angel Wong, Analyst for GBI Research, says: “Although the exact mechanisms that initiate PD’s onset are unclear, there is increasing knowledge of the neuroanatomy and fundamental molecular processes underlying PD neurodegeneration. This understanding is helped by the ongoing identification of both causative genes in familial PD and susceptibility genes.
“While a small number of first-in-class products target these genes, analysis shows a weak association between the genes and the known dysfunctional processes, suggesting that the former plays a minor role in contributing to PD. It is therefore likely that agents directly targeting the functional processes affected in PD have more chance of becoming effective treatments and transforming the future market landscape.”
The analyst adds that the 39 first-in-class targets have widely differing clinical and commercial potential, depending on how well their functional roles align to the pathophysiology of PD and the strength of evidence in Preclinical studies.
GBI Research also states that the 81 first-in-class products available for licensing and co-development deals represent vast investment opportunities in an arena not renowned for strategic consolidation.
Wong explains: “Future deal activities in PD treatment will be boosted by the increasing understanding of disease processes and the growing unmet need for disease-modifying therapies, resulting from an aging population.
“The diverse range of pipeline programs with first-in-class targets could therefore become an important addition to the marketed product landscape by offering opportunities for high-risk and high-return investment,” the analyst concludes.
*Frontier Pharma - Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance